Abstract:Respiratory diseases caused by influenza viruses still pose a serious concern to global health, and neutralizing antibodies constitute a promising area of antiviral therapeutics. However, the potential application of antibodies is often hampered by the challenge in generating nonimmunogenic antibodies in large scale. In the present study, transchromosomic (Tc) cattle were used for the generation of nonimmunogenic monoclonal antibodies (MAbs), and characterization of such MAbs revealed one monoclonal antibody, 53C10, exhibiting a potent neutralization activity against H1N1 influenza viruses. Further characterization of the neutralization escape mutant generated using this MAb showed that three amino acid substitutions in the HA head domain contributed to the resistance. These findings emphasize the importance of Tc cattle in the production of nonimmunogenic MAbs and highlight the potential of MAb 53C10 in the therapeutic application against H1 influenza virus infection in humans.

What problem does this paper attempt to address?

This paper aims to solve the key problems in the treatment of influenza viruses, especially the development and application of broadly neutralizing antibodies against the H1N1 subtype of influenza viruses. Specifically, the researchers used the transchromosomic (Tc) bovine platform to generate a human monoclonal antibody 53C10, which can effectively neutralize different clades of various H1N1 subtype influenza viruses. The following are the main objectives and findings of the paper: 1. **Development of non - immunogenic monoclonal antibodies**: - The researchers used the transgenic bovine platform to generate the human monoclonal antibody 53C10, solving the problem of difficult large - scale and rapid generation of non - immunogenic antibodies in traditional methods. - This method not only improves the production efficiency of antibodies but also ensures the low immunogenicity of antibodies in the human body. 2. **Neutralization of multiple H1N1 subtype influenza viruses**: - Through in vitro experiments, the researchers found that the 53C10 antibody can effectively neutralize multiple H1N1 subtype influenza viruses of different clades, including alpha, beta, gamma, and pdm09 clades. - However, 53C10 showed no neutralizing effect on the delta1 and delta2 clades of viruses, which may be because these clades have large antigenic differences from the pdm09, alpha, beta, and gamma clades. 3. **Identification of new conformational epitopes**: - Through experiments such as ELISA, Western Blot, and FACS, the researchers determined that the 53C10 antibody recognizes a new conformational epitope in the HA head domain, not a linear epitope. - Further escape mutation experiments revealed the roles of three key amino acid residues (G172, S207, and E212) in the recognition of the 53C10 antibody. Among them, the S207R mutation plays a decisive role in the resistance to 53C10, while the G172E and E212A mutations may play roles in maintaining the stability of the epitope structure. 4. **Potential therapeutic applications**: - The high - efficiency neutralizing ability and broad - spectrum activity of the 53C10 antibody against multiple H1N1 subtype influenza viruses make it have the potential as a potential drug for the treatment of human H1 influenza virus infections. In conclusion, this paper provides a new strategy to meet the treatment challenges of influenza viruses by developing and characterizing the 53C10 antibody, especially making important progress in generating non - immunogenic monoclonal antibodies. This achievement not only provides a new tool for the prevention and treatment of influenza viruses but also provides a reference for the treatment research of other viral diseases.

Human Monoclonal Antibody Derived from Transchromosomic Cattle Neutralizes Multiple H1 Clades of Influenza A Virus by Recognizing a Novel Conformational Epitope in the Hemagglutinin Head Domain

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Generation of Neutralizing and Non-Neutralizing Monoclonal Antibodies Against H7N9 Influenza Virus.

Identification and Structural Characterization of a Broadly Neutralizing Antibody Targeting a Novel Conserved Epitope on the Influenza Virus H5N1 Hemagglutinin

Evaluation of Panel of Neutralising Murine Monoclonal Antibodies and a Humanised Bispecific Antibody Against Influenza A(H1N1)pdm09 Virus Infection in a Mouse Model.

Rapid Generation Of Human-Like Neutralizing Monoclonal Antibodies In Urgent Preparedness For Influenza Pandemics And Virulent Infectious Diseases

An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies.

Generation of Human Neutralizing Monoclonal Antibodies Against the 2009 Pandemic H1N1 Virus from Peripheral Blood Memory B Lymphocytes.

Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses

A Human Antibody Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses

Identification of a cross-neutralizing antibody that targets the receptor binding site of H1N1 and H5N1 influenza viruses

Generation, Characterization and Epitope Mapping of Two Neutralizing and Protective Human Recombinant Antibodies Against Influenza A H5N1 Viruses.

The generation of hemagglutinin monoclonal antibodies against H9N2 influenza virus

Characterization of Neutralizing Monoclonal Antibodies and Identification of a Novel Conserved C-Terminal Linear Epitope on the Hemagglutinin Protein of the H9N2 Avian Influenza Virus

Preparation and characterization of mouse-derived monoclonal antibodies against the hemagglutinin of the H1N1 influenza virus

Humanized Antibodies with Broad-Spectrum Neutralization to Avian Influenza Virus H5N1.

Preclinical Pharmacokinetics of MHAA4549A, a Human Monoclonal Antibody to Influenza A Virus, and the Prediction of Its Efficacious Clinical Dose for the Treatment of Patients Hospitalized with Influenza A

A fully human monoclonal antibody possesses antibody‐dependent cellular cytotoxicity (ADCC) activity against the H1 subtype of influenza A virus by targeting a conserved epitope at the HA1 protomer interface

Vaccine-Induced Antibodies That Neutralize Group 1 and Group 2 Influenza A Viruses.

Characterization of Two Human Monoclonal Antibodies Neutralizing Influenza A H7N9 Viruses.

Fully Human Broadly Neutralizing Monoclonal Antibodies Against Influenza A Viruses Generated from the Memory B Cells of a 2009 Pandemic H1N1 Influenza Vaccine Recipient.